This clinical trial is focused on studying Multiple Sclerosis (MS), specifically the relapsing-remitting type, which is a condition where the immune system mistakenly attacks the protective covering of nerves, leading to communication problems between the brain and the rest of the body. The treatment being tested is called Ocrevus, which is a medication given through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The study is comparing two approaches to using Ocrevus: a personalized dosing method tailored to each patient’s needs and the standard method, which follows a fixed schedule.
The purpose of the study is to determine if the personalized dosing of Ocrevus is as effective as the standard dosing in controlling the activity of Multiple Sclerosis. Participants in the study will receive either the personalized or standard treatment and will be monitored over a period of time to assess the effectiveness of the treatment in preventing relapses and the development of new or enlarging lesions in the brain, which are areas of damage that can be seen on an MRI scan.
Throughout the study, participants will undergo regular check-ups and MRI scans to track their progress. The study aims to provide valuable information on whether adjusting the treatment to each individual’s needs can offer the same benefits as the traditional approach, potentially leading to more tailored and effective care for people with Multiple Sclerosis.
The Netherlands 
